[go: up one dir, main page]

WO2010150984A3 - Amorphous adefovir dipivoxil solid dispersion with improved stability, and method for preparing same - Google Patents

Amorphous adefovir dipivoxil solid dispersion with improved stability, and method for preparing same Download PDF

Info

Publication number
WO2010150984A3
WO2010150984A3 PCT/KR2010/003375 KR2010003375W WO2010150984A3 WO 2010150984 A3 WO2010150984 A3 WO 2010150984A3 KR 2010003375 W KR2010003375 W KR 2010003375W WO 2010150984 A3 WO2010150984 A3 WO 2010150984A3
Authority
WO
WIPO (PCT)
Prior art keywords
adefovir dipivoxil
solid dispersion
preparing same
amorphous
improved stability
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2010/003375
Other languages
French (fr)
Korean (ko)
Other versions
WO2010150984A2 (en
Inventor
원경재
모세명
채보람
송세현
손세일
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daewon Pharm Co Ltd
Original Assignee
Daewon Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daewon Pharm Co Ltd filed Critical Daewon Pharm Co Ltd
Publication of WO2010150984A2 publication Critical patent/WO2010150984A2/en
Publication of WO2010150984A3 publication Critical patent/WO2010150984A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to an amorphous adefovir dipivoxil solid dispersion with improved stability, and to a method for preparing same, and more particularly, to an adefovir dipivoxil solid dispersion containing adefovir dipivoxil and a hydrophilic polymer, and to a method for preparing same. The crystalline or amorphous adefovir dipivoxil solid dispersion containing amorphous adefovir dipivoxil and a hydrophilic polymer as active ingredients according to the present invention is thermodynamically stable at high temperature and high humidity conditions, and has excellent solubility. In addition, a preparation containing the amorphous adefovir dipivoxil solid dispersion has a high dissolution rate, and therefore can be useful in preventing or treating chronic hepatitis B.
PCT/KR2010/003375 2009-06-24 2010-05-27 Amorphous adefovir dipivoxil solid dispersion with improved stability, and method for preparing same Ceased WO2010150984A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020090056492A KR101121589B1 (en) 2009-06-24 2009-06-24 Amorphous adefovir dipivoxil solid dispersion having enhanced stability and preparation method thereof
KR10-2009-0056492 2009-06-24

Publications (2)

Publication Number Publication Date
WO2010150984A2 WO2010150984A2 (en) 2010-12-29
WO2010150984A3 true WO2010150984A3 (en) 2011-04-21

Family

ID=43386995

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/003375 Ceased WO2010150984A2 (en) 2009-06-24 2010-05-27 Amorphous adefovir dipivoxil solid dispersion with improved stability, and method for preparing same

Country Status (2)

Country Link
KR (1) KR101121589B1 (en)
WO (1) WO2010150984A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013029198A1 (en) * 2011-08-29 2013-03-07 天津泰普药品科技发展有限公司 Adefovir dipivoxil solid formulation and preparation method therefor
KR20170075090A (en) * 2015-12-22 2017-07-03 롯데정밀화학 주식회사 Oral pharmaceutical composition and manufacturing method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001041742A2 (en) * 1999-12-09 2001-06-14 Alza Corporation Antiviral medication
US20060025384A1 (en) * 2002-11-12 2006-02-02 Guocheng Wang New crystal form of adefovir dipivoxil and its composition
US20070059360A1 (en) * 2005-07-29 2007-03-15 Ashish Jaiswal Water-dispersible anti-retroviral pharmaceutical compositions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001041742A2 (en) * 1999-12-09 2001-06-14 Alza Corporation Antiviral medication
US20060025384A1 (en) * 2002-11-12 2006-02-02 Guocheng Wang New crystal form of adefovir dipivoxil and its composition
US20070059360A1 (en) * 2005-07-29 2007-03-15 Ashish Jaiswal Water-dispersible anti-retroviral pharmaceutical compositions

Also Published As

Publication number Publication date
WO2010150984A2 (en) 2010-12-29
KR20100138114A (en) 2010-12-31
KR101121589B1 (en) 2012-03-06

Similar Documents

Publication Publication Date Title
WO2009139576A3 (en) Pyridine derivatives substituted with novel benzoxazoles or pharmaceutically acceptable salts thereof, preparation method thereof and pharmaceutical compositions containing the same as active ingredients for prevention and treatment of abnormal cell growth disease
WO2012143568A3 (en) Liquid fuel composition
IL244239B (en) Process for preparing (2s,5r)-6-(benzyl/allyl)oxy-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboyxlic acid, its esters and salts
WO2012153193A3 (en) Protein-active agent conjugates and method for preparing the same
UA104517C2 (en) Solid composition useful for treating hepatitis c infection and method for its manufacturing
WO2012090043A8 (en) Novel solid state forms of azilsartan medoxomil and preparation thereof
WO2009122436A3 (en) An improved process for the preparation of morphinane analogues
MY169947A (en) Preparation of 6-aminocaproic acid from 5-formyl valeri c acid
WO2010018595A3 (en) Fosaprepitant dimeglumine intermediate, neutral fosaprepitant, and amorphous fosaprepitant dimeglumine and processes for their preparations
MX352758B (en) Improved methods for preparing squalene.
WO2013022847A3 (en) Wettable, non-leachable peat moss, method of preparation, and method of use
WO2012085927A3 (en) Tadalafil compositions
WO2013037609A3 (en) Method for adapting a hydrolytic enzyme to a component that stabilizes the hydrolytic enzyme
WO2011159129A3 (en) Novel rhodanine derivatives, method for preparing same, and pharmaceutical composition for the prevention or treatment of aids containing the rhodanine derivatives as active ingredients
WO2013071174A3 (en) Styrene-siloxane triblock copolymers as membranes for selective transport of alcohols and other organic compounds in aqueous mixtures
WO2010056039A3 (en) Oral pharmaceutical formulation of pelubiprofen with improved dissolution rate and stability
WO2012001705A3 (en) Pharmaceutical compositions of (r)-lansoprazole
WO2011117753A3 (en) Supramolecular complex flavor immobilization and controlled release
WO2013177172A3 (en) Herpesvirus compositions and related methods
JO3534B1 (en) Solid dispersion with improved solubility comprising tetrazole derivative as an active ingredient
WO2012122465A3 (en) Yeast with reduced 2,3-butanediol accumulation
WO2010037699A3 (en) Method for the pyrolysis of carbohydrates
WO2010150984A3 (en) Amorphous adefovir dipivoxil solid dispersion with improved stability, and method for preparing same
WO2010151008A3 (en) Piperazine dithioctate and pharmaceutical composition comprising the same
WO2012091308A3 (en) Polycarbonate-polysiloxane copolymer, and method for preparing same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10792266

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10792266

Country of ref document: EP

Kind code of ref document: A2